Globus Medical Inc. Class A Common Stock vs Vipshop Holdings Ltd - ADR — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Vipshop Holdings Ltd - ADR trades at $12.87 (market cap $6.12B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Vipshop Holdings Ltd - ADR pays a 4.81% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Vipshop Holdings Ltd - ADR for 50 Days on average.
| GMED | VIPS | |
|---|---|---|
Market Cap | $10.25B | $6.12B |
Volume | 1,108,124 | 2,098,592 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $20.29 |
52-Week Low | $58.33 | $12.09 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $9.76B | $2.94B |
Dividend Yield | — | 4.81% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Vipshop Holdings (VIPS) trades at $12.86, showing no change in the last session. The stock presents a compelling valuation with a P/E of 4.15 and P/S of 0.41, significantly below industry averages. Recent earnings have been mixed, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators show a bullish overall signal, though moving averages are bearish. Analyst consensus is positive with a 53.57% buy rating and a $16.17 price target, suggesting potential upside.
The outlook for VIPS is cautiously optimistic, driven by its attractive valuation and strong profitability metrics like a 24.44% ROE. However, risks include recent revenue declines and a challenging consumer environment in China. The stock's low multiples and positive cash flow from operations provide a margin of safety, but investors should monitor execution on future earnings and macroeconomic headwinds affecting consumer spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →